Airway calibre as a confounder in interpreting bronchial responsiveness in asthma

Asger Dirksen, Flemming Madsen, Thim Engel, Lars Frølund, John H Heinig, Holger Mosbech

Abstract

Background The relation between airway responsiveness to constrictor agents and forced expiratory volume in one second (FEV₁) is important when interpreting change in airway responsiveness after an intervention. The aim of the study was to analyse the relation between FEV₁, as a percentage of predicted values (% predicted) and airway responsiveness between and within asthmatic subjects.

Methods Results of non-specific bronchial challenge tests were pooled from two randomised crossover studies comparing the effect of a non-sedative antihistamine with placebo in 35 patients with moderate asthma. The design of the two studies was similar: the provocative concentration of either histamine (first study) or methacholine (second study) resulting in a 20% decrease in ventilatory capacity (PC₂₀) was repeated at two week intervals while patients were treated with the antihistamine or placebo. The dose of inhaled corticosteroid was gradually reduced during the study. Data were analysed with PC₂₀ as the dependent variable in a general linear model so that the influence on PC₂₀ of inhaled corticosteroid dose, antihistamine, and choice of bronchoconstricting agent could be separated from the influence of FEV₁ % predicted.

Results The correlation coefficient between mean PC₂₀ and mean prechallenge FEV₁ for each patient was 0.45. In the general linear model two thirds (65%) of the variation in PC₂₀ was due to variation between subjects. One third of the within subject variation in PC₂₀ could be explained by variation in prechallenge FEV₁ % predicted (a change in FEV₁ of 27% predicted was associated with one doubling or halving of PC₂₀). Treatment with the antihistamine had no influence on PC₂₀ except when histamine was used as the bronchoconstricting agent. The dose of inhaled corticosteroid had a small but significant effect.

Conclusions The variation in a patient’s PC₂₀ over time (several months) is related to changes in FEV₁ % predicted. Variation in FEV₁ % predicted explains less of the variation in bronchial responsiveness between subjects where a patient specific factor, which is probably related to the pathogenesis of bronchial asthma, seems to dominate.

(Thorax 1992;47:702-706)
Airway calibre as a confounder in interpreting bronchial responsiveness in asthma

Table 1: Characteristics of the 35 asthmatic patients studied

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean*</th>
<th>Range*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (No of men/women)</td>
<td>14/21</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>40</td>
<td>19–62</td>
</tr>
<tr>
<td>Duration of asthma (years)</td>
<td>17</td>
<td>2–31</td>
</tr>
</tbody>
</table>

Allergy

- Seasonal (%)                   | 29            |
- Perennial (%)                   | 57            |
- Smoking:
  - Never smoked (%)             | 68            |
  - Ex-smoker (%)                | 26            |
- Current smoker (%)             | 6             |

Height (cm)                      | 172           | 155–192      |

Baseline FEV₁:

| Litres                          | 2.92          | 1.68–5.20    |
| % Predicted                     | 82.5          | 53.0–118.0   |
| Baseline PC₂₀₅ (mg/ml)          | 0.68          | 0.03–7.00    |

*Unless otherwise specified.

Bronchial challenge tests were performed by means of a non-cumulative dose-response protocol. After an initial saline inhalation the patients inhaled unbuffered histamine dihydrochloride in the first study and methacholine chloride in the second study in doubling doses from 0.015 mg/ml to 16 mg/ml. The inhalations were performed for two minutes with intervals of five minutes between them. FEV₁ was recorded at 30 and 90 seconds after inhalation, and the inhalation was interrupted when a decrease of at least 20% of the post-saline FEV₁ was observed. At rechallenge the starting concentration of bronchoconstrictor was at least two steps below the previously observed PC₂₀₅ or 0.015 mg/ml.

The provocative concentration (PC₂₀₅) was calculated by linear interpolation between the last two points on the log dose-response curve. Interpolation between FEV₁ saline and FEV₁, threshold dose was never performed. The same Wright nebuliser was used throughout both studies. When driven by compressed air at 1.3 bar and a flow of 13 l/min, the output was 150 (SD 10) ml/min and the aerodynamic diameter for 99% of the dry particles was within 0.5–1.5 μm.

Patients abstained from bronchodilator treatment before each challenge. Study treatment (loratadine or placebo) and inhaled corticosteroids were continued unchanged. In accordance with our standard protocol we confirmed that patients had not had an infection, had not smoked for four hours and had not been exposed to relevant allergens or occupational agents.

**Statistical analysis**

The relation between prechallenge FEV₁ and bronchial responsiveness (PC₂₀₅) was summarised for each patient by plotting the results of the 12 challenge tests in a line derived from the regression model:

\[
\log₂ (PC₂₀₅) = k_0 + k_1 \times FEV₁,
\]

where the dependent variable PC₂₀₅ was logarithmically transformed to base 2. The purposes of the transformation were to stabilise variances, to linearise relations, to make distributions more normal, and to enable results to be presented in an acceptable scale of measurement.

The relation between PC₂₀₅ and other variables was further examined by fitting a general linear model:

\[
\log₂ (PC₂₀₅) = \text{Ptno} + \text{FEV₁} + \text{Ptno} \times \text{FEV₁} + \text{BDP} + \text{LHM},
\]

where Ptno is a patient specific factor (patient number) representing the variation in level of bronchial reactivity between asthmatics—that is, the interindividual variation in PC₂₀₅. FEV₁ is prechallenge FEV₁, as a quantitative variable (% predicted); Ptno * FEV₁ is an interaction term between the patient specific factor and prechallenge FEV₁ to test homogeneity of slopes (see figure 1). BDP is dosage of inhaled steroid as a quantitative covariate, and LHM is dose of antihistamine (L = loratadine) combined with type of bronchoconstricting agent (H = histamine and M = methacholine) as a qualitative factor with four categories: (a) no
antihistamine in two weeks before bronchial challenge with histamine; (b) no antihistamine in two weeks before bronchial challenge with methacholine; (c) loratadine 10 mg daily in the two weeks before bronchial challenge with histamine; and (d) loratadine 20 mg daily in two weeks before bronchial challenge with methacholine.

Results

The relation between bronchial responsiveness (PC_{20}) and FEV_1, % predicted is shown in figure 1. Despite individual variations in the slope of the lines there was a general tendency for increasing FEV_1 % predicted to be associated with increasing PC_{20}. The slope of the regression line for each patient and the standard deviation of the slope, with the mean slope and its 95% confidence interval, are shown in figure 2. The mean slope differed significantly from zero (p < 0.001).

The correlation coefficient (r) between mean PC_{20} and mean FEV_1 % predicted for each subject was 0.45 (p < 0.001), showing that some (r^2 = 20%) of the between subject variation in bronchial reactivity could be explained by between subject variation in prechallenge FEV_1 % predicted.

The results of the more comprehensive analysis of the variation in bronchial responsiveness (PC_{20}) in a general linear model are summarised in table 2. Almost two thirds (65%) of the variation in PC_{20} could be ascribed to a patient specific factor—that is, between subject variation in level of hyperresponsiveness. One third (35%) of the total variation in PC_{20} remained for within patient variation in responsiveness, and one third of this intra-individual variation (11% of the total variation in bronchial reactivity) could be ascribed to within subject variation in prechallenge FEV_1 % predicted (p < 0.001). The coefficient of prechallenge FEV_1 % predicted in the general linear model was 0.037 doublings/% predicted FEV_1, indicating that an increase in FEV_1 by 27% of predicted values was associated with a doubling of PC_{20}.

The interaction term between prechallenge FEV_1 % predicted and the patient specific factor did not reach significance (p = 0.09), which means that the variation in slope of individual patients in figures 1 and 2 can be explained by residual variation—that is, the low reproducibility of PC_{20} and FEV_1 measurements. This means that the mean slope of the regression lines in figure 1 should be considered in predicting PC_{20} and that individual variation in the slope of the regression lines is less important.

Inhaled steroid dosage was a significant covariate (p < 0.05), although less than 1% of the total variation in PC_{20} was explained by this variable. The interaction term including dose of antihistamine and type of bronchoconstricting agent was highly significant (p < 0.001), accounting for 5% of the variation in bronchial hyperresponsiveness. This factor had four categories and further analysis showed that the combination of loratadine 10 mg daily with histamine as the challenge drug differed from the three other categories and that the differences between the three other categories were insignificant, or they had no influence on PC_{20}.

Discussion

It has been recognised since the 1960s that people with poorer lung function tend to have greater degrees of non-specific airway responsiveness. This relation has now been well documented in population samples and among cigarette smokers with chronic airflow obstruction and chronic mucus hypersecretion, but conflicting data have been reported on the

<table>
<thead>
<tr>
<th>Source of variation</th>
<th>Mean (SD) coefficient</th>
<th>% of variation explained</th>
<th>F statistic</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main effects:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient specific factor (patient number)</td>
<td>—</td>
<td>65</td>
<td>0.076</td>
<td></td>
</tr>
<tr>
<td>FEV_1 (% predicted)</td>
<td>0.037 (0.010)</td>
<td>11</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Inhaled steroid (mg/day)</td>
<td>0.863 (0.415)</td>
<td>0</td>
<td>0.038</td>
<td></td>
</tr>
<tr>
<td>Two way interactions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV_1 patient specific factor</td>
<td>—</td>
<td>3</td>
<td>0.091</td>
<td></td>
</tr>
<tr>
<td>Antihistamine bronchoconstrictor*</td>
<td>—</td>
<td>5</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Explained by model</td>
<td>84</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residual variation</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FEV_1 = prechallenge FEV_1 (% predicted).

*Combined dose of antihistamine (loratadine 0 mg, 10 mg, or 20 mg) with choice of histamine or methacholine for the bronchial challenge (for further details see text).
correlation between lung function and degree of airway responsiveness among asthmatic subjects. In a study by Yan et al of 17 subjects with asthma identified on the basis of a doctor’s diagnosis or intermittent wheezing or dyspnoea there was no significant correlation between lung function before challenge and PD_{20} FEV_{1}. Rubenfeld and Pain observed no significant correlation between methacholine airway responsiveness and prechallenge specific airway conductance among 11 asthmatic volunteers with a wide range of prechallenge conductance, and Chung et al concluded that bronchial hyperreactivity in asthmatic subjects is unlikely to be a direct consequence of a low starting airway calibre. In contrast, Cockcroft et al observed a significant direct correlation between prechallenge FEV_{1} and PC_{20} FEV_{1} (r = 0.49) among 156 patients with well controlled atopic asthma, and a smaller study of 15 asthmatic subjects gave a similar correlation of 0.42. In our study we found a correlation coefficient of 0.45.

In most studies bronchial reactivity has been measured on only a single occasion in each patient, and consequently investigators could analyse only between subject variation in bronchial responsiveness and ventilatory capacity. In a more recent longitudinal study of 20 asthmatic subjects reactivity to methacholine was measured every two to three weeks for 12 to 18 months. The aim of this study and therefore the statistical analyses differed from that of our study, however. The subjects’ overall reactivity (median PD_{20}) was related only to average variation in PEF, and the temporal relation between trends in PD_{20} and PEF and FEV_{1} within subjects was based on subjective interpretation of charted serial data in individual patients. The statistical analysis of the data was confined to Spearman’s ρ, which did not take into account the possibility that treatment may have modified the degree of reactivity.

In our study non-specific airway responsiveness was measured 12 times in each patient at intervals of two (or more) weeks, which enabled us to analyse the within patient relation between prechallenge FEV_{1} % predicted and bronchial reactivity (PC_{20}). The analysis was performed in a general linear model in which the influence of an inhaled corticosteroid, an antihistamine, and a choice of bronchoconstricting agent on bronchial hyperresponsiveness could be separated from the influence of FEV_{1} % predicted.

Histamine and methacholine produce bronchoconstriction by different mechanisms, and a person’s sensitivity to these different agents may vary. None the less, among asthmatic subjects a high correlation has been observed between methacholine and histamine responsiveness. In our general linear model splitting the LHM term into separate categories for bronchial challenge with histamine and challenge with methacholine did not improve the explanatory power of the model, and thus pooling of data from two studies differing with regard to bronchoconstricting agent was considered to be acceptable. Only a modest part of the variation in bronchial hyperresponsiveness could be explained by the effect of drugs (loratadine and inhaled corticosteroids).

Two thirds (65%) of the total variation in bronchial responsiveness could be ascribed to between subject variation, leaving one third of the variation to be explained by within subject variation. Only 16% of the total variation in non-specific airway responsiveness was not accounted for by the explanatory variables of the model.

The analysis showed that prechallenge FEV_{1} % predicted was a strong explanatory variable for between subject and especially within subject variation in bronchial responsiveness. The close within subject relation between prechallenge level of pulmonary function and degree of responsiveness to the bronchoconstricting agents may be explained in part at least by geometric factors. Because the resistance of a tube is inversely related to its radius to the fourth power, a given degree of circumferential shortening of bronchial smooth muscle will cause a greater increase in airway resistance in a narrower airway than in a wider airway.

In addition to bronchoconstriction, asthma involves several mechanisms that may influence airway responsiveness. Partial airway inflammation may alter the local production of lipid derived inflammatory mediators, impair local neuroregulation, and damage respiratory epithelium, possibly interfering with production of a putative epithelial derived relaxation factor. These mechanisms, which are probably part of the pathogenesis of bronchial asthma, may increase airway reactivity without concomitant narrowing of the airway and would explain why most of the between subject variation in bronchial responsiveness was not related to FEV_{1} % predicted.

The results of a multivariate analysis of the relation between bronchial responsiveness to non-specific bronchoconstrictors and airway calibre will depend on the selection of subjects for the study. All our patients had asthma with documented reversible airway obstruction and most were atopic and had not smoked cigarettes. Any admixture of normal subjects or patients who smoke and have chronic obstructive lung disease would be likely to strengthen the relation between airway responsiveness and FEV_{1} % predicted.

In conclusion, we found a large variation in bronchial responsiveness to histamine or methacholine between asthmatic subjects that was only moderately related to prechallenge FEV_{1} % predicted. Variation in FEV_{1} % predicted explained one third of the variation in the response of an individual patient, however, when bronchial challenge was repeated. The effect of an inhaled corticosteroid was small, and treatment with an antihistamine was important only when histamine was used as the bronchoconstricting agent.

The practical clinical aspect of our findings is that airway responsiveness cannot be predicted with any precision from an asthmatic patient’s FEV_{1} % predicted. Once bronchial reactivity has been determined, however, subsequent
monitoring of bronchial responsiveness partly mirrors changes in FEV₁, which can be monitored easily.

We thank Aksel Bertelsen from the Statistical Research Unit of the University of Copenhagen for statistical advice and for performing the general linear modelling in SAS (statistical analysis system).


Airway calibre as a confounder in interpreting bronchial responsiveness in asthma.

A Dirksen, F Madsen, T Engel, L Frølund, J H Heinig and H Mosbech

Thorax 1992 47: 702-706
doi: 10.1136/thx.47.9.702

Updated information and services can be found at: http://thorax.bmj.com/content/47/9/702

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/